Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1Breast 1

Conditions

Breast Neoplasms 30HR+/HER2- Advanced Breast Cancer 3Breast Cancer Metastatic 3Advanced Breast Cancer 2Triple Negative Breast Neoplasms 1HR Positive HER2 Negative Advanced Breast Cancer 1HER2-positive Breast Cancer 1Breast Neoplasm Female 1Breast Diseases 1Brain Neoplasms 1Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed 1

Interventions

Trastuzumab 18Radiosurgery 15Capecitabine 13Lapatinib 11Radiotherapy 9Magnetic Resonance Spectroscopy 9trastuzumab deruxtecan 7Temozolomide 6tucatinib 4pembrolizumab 4paclitaxel-Angiopep-2 conjugate 4eribulin 4Vinorelbine 4Specimen Handling 4Paclitaxel 4Methotrexate 4Cisplatin 4sacituzumab govitecan 3pyrotinib 3abemaciclib 3Radiation 3Fluorodeoxyglucose F18 3pertuzumab 2palbociclib 2neratinib 2durvalumab 2cediranib 2cabazitaxel 2Sodium Chloride 2Observation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Brain Neoplasms × dalpiciclib × Breast × Clear all
NCT07539753 2026-04-30

Brain Radiotherapy Combined With Dalpiciclib and Endocrine Therapy in HR-Positive/HER2-Negative Advanced Breast Cancer With Brain Metastases

Nanfang Hospital, Southern Medical University

Phase 2 Not yet recruiting
46 enrolled
BreastCNS

Brain Neoplasms, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡